The theranostics market size has grown rapidly in recent years. It will grow from $122.98 billion in 2025 to $136.02 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to advancements in molecular diagnostics, increased prevalence of chronic diseases, growth of oncology-focused research programs, availability of targeted therapeutics, expansion of diagnostic laboratory infrastructure.
The theranostics market size is expected to see rapid growth in the next few years. It will grow to $205.54 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising investments in precision medicine, growing adoption of ai-driven diagnostic tools, expansion of theranostic applications in oncology, increasing integration of genomics into clinical practice, higher demand for personalized treatment outcomes. Major trends in the forecast period include increasing integration of diagnostics with targeted therapies, rising adoption of personalized medicine platforms, growing use of molecular imaging techniques, expansion of companion diagnostic development, enhanced focus on patient-specific treatment pathways.
The rising prevalence of cancer is expected to drive growth in the theranostics market in the coming years. Cancer, characterized by uncontrolled cell growth, affects various organs and contributes significantly to global morbidity and mortality. Theranostics, which combines therapeutics and diagnostics, offers promising potential in managing cancer and other chronic diseases. This approach enables personalized, targeted treatments by integrating diagnostic and therapeutic capabilities, creating opportunities for innovation in healthcare. For example, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that over 3 million people in the UK were living with cancer in 2024, with projections rising to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the theranostics market.
Key companies in the theranostics market are developing advanced solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by combining diagnostics and therapeutics into a single treatment approach. Theranostics clinical trials evaluate the use of diagnostic tests alongside targeted therapies to tailor treatments for individual patients. These trials aim to assess the effectiveness of therapies based on patient-specific biomarkers, advancing personalized medicine. For instance, in May 2024, BAMF Health, a US-based cancer treatment center, launched the COMBAT Trial, officially titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). The trial leveraged BAMF Health's rapid activation program, BAMF RapAct, enabling launch in just seven weeks, and utilized innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR) to expand treatment options for patients with limited therapies.
In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceuticals, acquired Pharma15 Corporation for $4 million. Through this acquisition, Radiopharm aims to explore next-generation radiopharmaceuticals for prostate cancer treatment, focusing on advancing beyond PSMA-based therapies and delivering innovative solutions for patients. Pharma15 Corporation, based in the US, specializes in the development of radio-immuno-theranostic platforms and pharmaceutical products.
Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.
North America was the largest region in the global theranostics market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the theranostics market by increasing costs of imported diagnostic reagents, imaging agents, sequencing equipment, and targeted therapeutic compounds. Research institutions and hospitals in North America and Europe are most affected due to dependence on imported high-value consumables and instruments, while Asia-Pacific faces cost pressures on advanced diagnostic manufacturing. These tariffs are increasing development and deployment costs. However, they are also encouraging domestic production of diagnostic kits, regional innovation in molecular imaging technologies, and stronger local supply chains for precision medicine solutions.
The theranostics market research report is one of a series of new reports that provides theranostics market statistics, including theranostics industry global market size, regional shares, competitors with a theranostics market share, detailed theranostics market segments, market trends and opportunities, and any further data you may need to thrive in the theranostics industry. This theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Theranostics is a medical discipline that combines therapeutics and diagnostics into a unified approach. It focuses on developing and using diagnostic tests that not only detect diseases or conditions but also provide information to guide personalized treatment interventions.
The main types of theranostics are categorized by disease type, including neurological disorders, cardiovascular diseases, immunological disorders, oncology, and others. Neurological disorders encompass a variety of conditions affecting the brain, spinal cord, and nerves, leading to different symptoms and impairments. Theranostics is used to enable accurate diagnosis, monitor disease progression, and guide personalized treatment for these conditions. Treatments are delivered using various theranostics technologies, such as polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others, and are utilized by end-users including hospitals, clinics, diagnostic laboratories, and more.
The theranostics market consists of revenues earned by entities by providing genetic testing, targeted therapy services, contract development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The theranostics market also includes of sales of companion diagnostics, nanomedicine and 2D nano-theranostics materials. Values in this market are """"factory gate"""" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The theranostics market size is expected to see rapid growth in the next few years. It will grow to $205.54 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising investments in precision medicine, growing adoption of ai-driven diagnostic tools, expansion of theranostic applications in oncology, increasing integration of genomics into clinical practice, higher demand for personalized treatment outcomes. Major trends in the forecast period include increasing integration of diagnostics with targeted therapies, rising adoption of personalized medicine platforms, growing use of molecular imaging techniques, expansion of companion diagnostic development, enhanced focus on patient-specific treatment pathways.
The rising prevalence of cancer is expected to drive growth in the theranostics market in the coming years. Cancer, characterized by uncontrolled cell growth, affects various organs and contributes significantly to global morbidity and mortality. Theranostics, which combines therapeutics and diagnostics, offers promising potential in managing cancer and other chronic diseases. This approach enables personalized, targeted treatments by integrating diagnostic and therapeutic capabilities, creating opportunities for innovation in healthcare. For example, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that over 3 million people in the UK were living with cancer in 2024, with projections rising to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the theranostics market.
Key companies in the theranostics market are developing advanced solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by combining diagnostics and therapeutics into a single treatment approach. Theranostics clinical trials evaluate the use of diagnostic tests alongside targeted therapies to tailor treatments for individual patients. These trials aim to assess the effectiveness of therapies based on patient-specific biomarkers, advancing personalized medicine. For instance, in May 2024, BAMF Health, a US-based cancer treatment center, launched the COMBAT Trial, officially titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). The trial leveraged BAMF Health's rapid activation program, BAMF RapAct, enabling launch in just seven weeks, and utilized innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR) to expand treatment options for patients with limited therapies.
In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceuticals, acquired Pharma15 Corporation for $4 million. Through this acquisition, Radiopharm aims to explore next-generation radiopharmaceuticals for prostate cancer treatment, focusing on advancing beyond PSMA-based therapies and delivering innovative solutions for patients. Pharma15 Corporation, based in the US, specializes in the development of radio-immuno-theranostic platforms and pharmaceutical products.
Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.
North America was the largest region in the global theranostics market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the theranostics market by increasing costs of imported diagnostic reagents, imaging agents, sequencing equipment, and targeted therapeutic compounds. Research institutions and hospitals in North America and Europe are most affected due to dependence on imported high-value consumables and instruments, while Asia-Pacific faces cost pressures on advanced diagnostic manufacturing. These tariffs are increasing development and deployment costs. However, they are also encouraging domestic production of diagnostic kits, regional innovation in molecular imaging technologies, and stronger local supply chains for precision medicine solutions.
The theranostics market research report is one of a series of new reports that provides theranostics market statistics, including theranostics industry global market size, regional shares, competitors with a theranostics market share, detailed theranostics market segments, market trends and opportunities, and any further data you may need to thrive in the theranostics industry. This theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Theranostics is a medical discipline that combines therapeutics and diagnostics into a unified approach. It focuses on developing and using diagnostic tests that not only detect diseases or conditions but also provide information to guide personalized treatment interventions.
The main types of theranostics are categorized by disease type, including neurological disorders, cardiovascular diseases, immunological disorders, oncology, and others. Neurological disorders encompass a variety of conditions affecting the brain, spinal cord, and nerves, leading to different symptoms and impairments. Theranostics is used to enable accurate diagnosis, monitor disease progression, and guide personalized treatment for these conditions. Treatments are delivered using various theranostics technologies, such as polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others, and are utilized by end-users including hospitals, clinics, diagnostic laboratories, and more.
The theranostics market consists of revenues earned by entities by providing genetic testing, targeted therapy services, contract development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The theranostics market also includes of sales of companion diagnostics, nanomedicine and 2D nano-theranostics materials. Values in this market are """"factory gate"""" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Theranostics Market Characteristics
3. Theranostics Market Supply Chain Analysis
4. Global Theranostics Market Trends and Strategies
5. Theranostics Market Analysis of End Use Industries
7. Global Theranostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Theranostics Total Addressable Market (TAM) Analysis for the Market
9. Theranostics Market Segmentation
10. Theranostics Market Regional and Country Analysis
11. Asia-Pacific Theranostics Market
12. China Theranostics Market
13. India Theranostics Market
14. Japan Theranostics Market
15. Australia Theranostics Market
16. Indonesia Theranostics Market
17. South Korea Theranostics Market
18. Taiwan Theranostics Market
19. South East Asia Theranostics Market
20. Western Europe Theranostics Market
21. UK Theranostics Market
22. Germany Theranostics Market
23. France Theranostics Market
24. Italy Theranostics Market
25. Spain Theranostics Market
26. Eastern Europe Theranostics Market
27. Russia Theranostics Market
28. North America Theranostics Market
29. USA Theranostics Market
30. Canada Theranostics Market
31. South America Theranostics Market
32. Brazil Theranostics Market
33. Middle East Theranostics Market
34. Africa Theranostics Market
36. Theranostics Market Competitive Landscape and Company Profiles
37. Theranostics Market Other Major and Innovative Companies
40. Theranostics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Theranostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for theranostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The theranostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Neurological Disorders: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Epilepsy2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension
3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis
4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer
5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders
Companies Mentioned: Abbott Laboratories; Agilent Technologies Inc.; Beckman Coulter Inc.; Thermo Fisher Scientific Inc; Astellas Pharma; Radiopharm Theranostics Ltd; Alpha-Theranostics; Cardio-Theranostics LLC; Curium; Theradiag; Cell Theranostics; F. Hoffmann-La Roche AG; GE HealthCare Technologies Inc; Qiagen NV; Foundation Medicine Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Siemens Healthineers; Advanced Accelerator Applications; AstraZeneca plc; Bayer AG; Bio-Rad Laboratories; Bristol-Myers Squibb Company; Danaher Corporation; Illumina Inc.; Merck KGaA; Roche Diagnostics Corporation; PerkinElmer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Theranostics market report include:- Abbott Laboratories
- Agilent Technologies Inc.
- Beckman Coulter Inc.
- Thermo Fisher Scientific Inc
- Astellas Pharma
- Radiopharm Theranostics Ltd
- Alpha-Theranostics
- Cardio-Theranostics LLC
- Curium
- Theradiag
- Cell Theranostics
- F. Hoffmann-La Roche AG
- GE HealthCare Technologies Inc
- Qiagen NV
- Foundation Medicine Inc.
- Leica Biosystems Nussloch GmBH
- Pfizer Inc.
- Siemens Healthineers
- Advanced Accelerator Applications
- AstraZeneca plc
- Bayer AG
- Bio-Rad Laboratories
- Bristol-Myers Squibb Company
- Danaher Corporation
- Illumina Inc.
- Merck KGaA
- Roche Diagnostics Corporation
- PerkinElmer Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 136.02 Billion |
| Forecasted Market Value ( USD | $ 205.54 Billion |
| Compound Annual Growth Rate | 10.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
